The Safety and Biological Activity of OTT166, a Novel Topical Selective Integrin Inhibitor for the Treatment of Diabetic Eye Disease : A Phase 1b Study
BACKGROUND AND OBJECTIVES: To evaluate the safety, tolerability, and biological activity of a topical selective integrin inhibitor (OTT166) eyedrop administered BID for diabetic retinopathy (DR) and diabetic macular edema (DME)
Bibliographische Detailangaben
| Veröffentlicht in: | Ophthalmic surgery, lasers & imaging retina. - 2013. - 53(2022), 10 vom: 17. Okt., Seite 553-560
|
|---|
| 1. Verfasser: |
Boyer, David S
(VerfasserIn) |
|---|
| Weitere Verfasser: |
Kaiser, Peter K,
Magrath, George N,
Brady, Kerrie,
Edwards, Scott,
Tanzer, David J,
Heier, Jeffrey S |
|---|
| Format: | Online-Aufsatz
|
|---|
| Sprache: | English |
|---|
| Veröffentlicht: |
2022
|
|---|
| Zugriff auf das übergeordnete Werk: | Ophthalmic surgery, lasers & imaging retina
|
|---|
| Schlagworte: | Clinical Trial, Phase I
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Integrins
Ophthalmic Solutions |
|---|